Evidence map›Paper›PMID 40006600›Full record

ArticlePharmaceutics2025

Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models.

Atziri Corin Chavez Alvarez, Chahrazed Bouzriba, Vincent Ouellette, Mathieu Gagné-Boulet, Alexandre Patenaude, Sylvie Pilote, René C-Gaudreault, Chantale Simard, Sébastien Fortin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Atziri Corin Chavez AlvarezFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0002-5514-7144
Chahrazed BouzribaFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0003-3743-1210
Vincent OuelletteFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0001-5224-4419
Mathieu Gagné-BouletFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.
Alexandre PatenaudeCentre de Recherche du CHU de Québec-Université Laval, Axe Oncologie, Hôpital Saint-François d'Assise, 10 Rue de l'Espinay, Québec, QC G1L 3L5, Canada.
Sylvie PiloteCentre de Recherche de l'Institut Universitaire de Cardiologie et Pneumologie de Québec-Université Laval, Axe Cardiologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte-Foy, Québec, QC G1V 4G5, Canada.
René C-GaudreaultCentre de Recherche du CHU de Québec-Université Laval, Axe Oncologie, Hôpital Saint-François d'Assise, 10 Rue de l'Espinay, Québec, QC G1L 3L5, Canada.
Chantale SimardFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0003-4098-0480
Sébastien FortinFaculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0002-3374-2751

Funding

Canada Foundation for Innovation 36231CIHR PJT-178096Fonds de Recherche du Québec-Santé N/ARéseau québécois de recherche sur les médicaments N/AUniversité Laval N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anticancer agentsantimitoticsantitumor activityCYP1A1half-lifeprodrugstoxicity evaluation

Identifiers

PMID40006600
PMCPMC11859775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.